Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2022

View Archived Issues

TMID enzymes as potential antiviral targets for the treatment of HHV infections

Researchers improve cisplatin-induced ototoxicity model

Anti-VISTA HMBD-002 antibody blocks VISTA-induced immunosuppression in preclinical models

Chinese researchers identify new CRBN modulators

Eccogene divulges new GLP-1R agonists

Reaction Biology presents new HDAC inhibitors

Challenge Bioproducts synthesizes new PTGER4 ligands

Customization of regulatory elements in hearing loss gene therapies using AAVAnc80 vectors

Zp Spv 3 K/S describes complement C3 inhibitors

Advanced prostate cancer antibody successful in dogs

Researchers unveil new miRNAs tied to cerebral cavernous angioma

PNV-5032 reduces airflow resistance by 25% in animal test of allergen-induced asthma

Akso and Huadong Medicine sign collaborative agreement for AB-002 in Asia Pacific region

Investigators find a role for miR-206 in intracerebral hemorrhage

JR-14a shows potent neuroprotective effect in stroke models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...